InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,214.80
(
0.00%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.33
(
-0.17%
)
Bitcoin
60,676.08
(
-0.22%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mblimon post# 4453

Thursday, 08/02/2007 2:51:45 PM

Thursday, August 02, 2007 2:51:45 PM

Post# of 19309
>…the time for DNA/BIIB's [CD20] product to become generic is not that long.<

I do not understand why you say this. In the U.S., the patents of greatest consequence for a second-generation humanized mAb have not even issued yet. Here’s an excerpt from BIIB’s latest 10K report:

http://www.sec.gov/Archives/edgar/data/875045/000095013507000981/b63632bie10vk.htm

>>
Our recently-granted patent in certain European countries claiming the treatment with anti-CD-20 antibodies of certain auto-immune indications, including rheumatoid arthritis, has been opposed by numerous third parties. This opposition proceeding is likely to be protracted and its outcome is uncertain at this time.

…In addition, we and our collaborator, Genentech, have filed numerous patent applications directed to anti-CD-20 antibodies and their uses to treat various diseases. These pending patent applications have the potential of issuing as patents in the U.S. and abroad covering anti-CD-20 antibody molecules for periods beyond that stated above for RITUXAN and ZEVALIN.
<<

Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up